What advancement made transfusions safer?

The discovery of blood groups, specifically the ABO system identified by Karl Landsteiner in 1901, was the pivotal advancement that made blood transfusions significantly safer. Before this discovery, transfusions were unpredictable and often fatal because recipients frequently suffered severe hemolytic reactions when incompatible blood was infused. Understanding that human blood falls into distinct antigenic categories — A, B, AB, and O — allowed clinicians to match donor and recipient blood before transfusion, dramatically reducing life-threatening incompatibility reactions. This discovery earned Landsteiner the Nobel Prize in Physiology or Medicine in 1930. The Rh factor, identified later, further refined compatibility testing. Synthetic blood, while a subject of ongoing research, has not yet achieved widespread clinical use and did not historically make transfusions safer. Blood storage techniques, including anticoagulants and refrigeration, improved the logistics and availability of transfusions but were not the primary safety breakthrough — incompatibility reactions remained the dominant cause of transfusion-related deaths. Advanced surgery improved operative outcomes broadly but did not directly address the immunological basis of transfusion danger. Thus, the identification of blood groups remains the foundational safety advancement in transfusion medicine, addressing the root cause of most fatal transfusion reactions.